SelenBio, Inc. is a biotechnology company developing antibacterial technology for a wide variety of use cases. Our platform antibacterial technology prevents biofilm formation in medical, dental, industrial, and consumer applications using a unique and proprietary selenium-based compound. SelenBio keeps you happy and healthy by keeping the products you use and the things you touch infection-free.

The Company is planning to raise a total of $2 million, of which $1.1 million has been raised to-date.

Bacteria can infect any part of the human body. Infectious bacteria reproduce quickly in your body and can make you very ill. Many bacteria give off toxins, which can damage tissue and even become life-threatening.

The risk of severe infections is especially high around implanted medical devices such as hernia meshes, orthopedic implants, catheters, and vascular grafts.

Recent changes in healthcare reimbursement policy have shifted the cost of implant infections back to the original service provider as a “preventable infection,” generating an urgent need to develop devices better able to prevent bacterial and fungal infections.

Current silver and copper-based antimicrobials used for treatment of bacterial growth are costly and carry harmful side effects due to their toxicity and leaching.

What is biofilm?

SelenBio developed and is currently manufacturing a selenium-based organic compound that can be integrated into products. This compound kills harmful bacteria for the life of the product.

SELDOX®, developed at Texas Tech University and licensed and commercialized exclusively by SelenBio, Inc. is an innovative and proven antimicrobial compound derived from the element selenium. When integrated into any material or product, SELDOX® works by generating superoxide radicals which destroy bacteria on contact, disrupting colonization and preventing the formation of biofilm.

SelenBio engages in joint development with numerous industry partners in large markets where harmful bacteria creates problems and increases costs. We collaborate with those partners to create products with added antibacterial characteristics. When successfully completed, these products prevent dangerous bacteria from growing on the surface of the product.

The Company currently has joint-development projects underway in the medical device industry (i.e. wound care bandages, silicone used in manufacturing urinary catheters, etc.), the commercial paint industry to prevent bacterial growth in hospitals, nursing homes, schools, etc., and consumer products like water bottles and athletic clothing.

SelenBio plans to receive licensing fees from these companies for the use of their patented technology in addition to ongoing royalty payments from the sale of these products.

Below are just two examples of the market size for only two (2) current applications of SELDOX® technology.

Market Opportunity

SelenBio, Inc.’s SELDOX® technology has the potential to be disruptive within the antimicrobial industry. The Company plans to identify industries and applications in which its SELDOX® platform antimicrobial technology can offer either an improved clinical outcome or significantly reduced cost.

In recent years, there has been an increased need for new antibacterial agents as the emergence of bacterial resistance now poses a significant clinical problem. More and more bacteria are becoming resistant to conventional antibacterial therapies and treatments. For example, meticillin-resistant Staphylococcus aureus(MRSA) and vancomycin-resistant enterococci (VRE) are both increasingly dangerous. SelenBio’s SELDOX® is timely, advantageous, and cost-effective.

Antibiotic resistance adds nearly $1,400 to the average hospital bill for treating a bacterial infection and costs the U.S. more than $2 billion annually, according to a March 22, 2018 study conducted by Health Affairs. And that number is likely much higher, since the data did not include patients in nursing homes, skilled nursing facilities, prisons, or other institutional sites of care. The study, which is the first national estimate of the incremental costs for treating antibiotic-resistant infections, also found that the share of bacterial infections in the United States that were antibiotic resistant more than doubled over 13 years, rising from 5.2% in 2002 to 11% in 2014.

The antibacterial activity of silver has long been known because of its toxicity to human cells. The most widely documented uses are prophylactic treatment of burns, wounds, incisions and water disinfection. However, the mechanisms by which silver kills cells are not known. It is believed that silver ions leach from the treated surface potentially causing harm to bystander cells and eventually diminishing in effectiveness.

SELDOX® is unique in its qualities as an antimicrobial:

1. It is catalytic:
   As long as oxygen & sulfur/thiol groups(both ubiquitous) are present, SELDOX® will not stop fighting bacteria.
2. It is non-leaching:
   Whereas other antimicrobials such as silver and copper leach into the environment, body or water supply, SELDOX® remains covalently bound to a substrate with no reduction in potency nor intrusion into the surrounding environment.
3. It is safe:
   SELDOX® is non-toxic, safe in and on the body, and selenium is in fact nutritionally required by the body.
4. It is cost effective:
   SELDOX® is a fraction of the cost of silver and other antimicrobials.
5. It is cleared by the FDA:
   SELDOX® has been cleared by the FDA and is commercially in use today in various dental products, and 6) it is highly effective – SELDOX® has achieved 99.99% (and higher) effectiveness in killing numerous key bacteria, fungus and viruses, making it antibacterial, antifungal and virucidal.

SELDOX® platform antimicrobial technology provides competitive advantage and scaling opportunities in the following ways:

• Multiple Revenue Sources:
  Revenue will be realized both from royalty and fees charged for sublicensing and also from the sale of SELDOX® antimicrobial compound. Ultimately, as the technology matures, revenue can also be received from fees charged from offering Research & Development services to prospective sublicensee’s.
• Recurring Revenue:
  Once a sublicense has been executed for an application(s) in a particular industry, SelenBio, Inc. will receive ongoing royalties and fees for the remaining life of the patent (2030).
• Platform Based Instead of Single Product:
  The countless number of applications that can benefit from an antimicrobial enhancement mitigates the investment risk.
• Network Effect In Action:
  The value of the technology (company) increases with the number of users (sublicensee’s).
• Virality:
  Not the same as “network effect” in that users invite (attract) other users.

This is how we acquire new customers, develop new markets and bring our revolutionary technology to the world:

1. SelenBio, Inc identifies industries and applications in which its SELDOX® platform antimicrobial technology can offer either an improved clinical outcome or significantly reduced cost.
2. We then consider each potential application’s market opportunity, barriers to entry, and existing competitive landscape to determine whether a SelenBio branded product entry or strategic sublicense partnership is more appropriate.
3. SelenBio directly approaches targeted industries or partners with a competitive advantage and value driven proposition. Commercialized applications are sold through distributors, manufacturer sales organizations or through established direct sales channels of sublicensee, with support and supplemental marketing activity provided by SelenBio.
4. SelenBio will be the sole and exclusive provider of SELDOX® compound to all sublicensees.
5. We maintain an active web and social media presence and participate in industry-relevant trade shows, expos, and conferences nationwide to educate consumers and business partners of the availability and advantages of our products.

Sublicensed integration of SELDOX® into raw materials to reach downstream product applications is an area of particular interest – this will allow us to maintain a lean operation while reaching broader markets.

1. DenteShield™ dental products launched January 2018
2. European patents validated in 11 countries April 2018
3. Discussion started on integration of SELDOX® into silicone for use in urinary catheters and other medical devices June 2018
4. Joint development of wound care bandage began July 2018
5. R&D on incorporating SELDOX® into glaucoma tube October 2018
6. Integration and successful testing with paint application
7. Sublicense agreement signed for textile (cotton) application June 2019
8. GingiShield™ antibacterial dental sealant launched July 2019

SelenBio Receives FDA Approval For New Biotechnology to Alleviate High Cost in Eliminating Bacteria SelenBio, Inc. obtains FDA approval

Texas-Based Biotech Company To Launch FDA-Approved Product Geared Toward Healthier Pets SelenBio launches GingiShield

• SelenBio.com
• Facebook
• Twitter
• Instagram